Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype

Saved in:
Bibliographic Details
Published inLeukemia Vol. 26; no. 4; pp. 822 - 824
Main Authors SCHERMAN, E, MALAK, S, PEROT, C, GORIN, N. C, RUBIO, M. T, ISNARD, F
Format Journal Article
LanguageEnglish
Published Avenel, NJ Nature Publishing Group 01.04.2012
Springer Nature
Subjects
Acute myeloid leukemia
Adult
Aged
Anemia
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Azacitidine - administration & dosage
Biological and medical sciences
Care and treatment
Diagnosis
Dysplasia
Female
Hematologic and hematopoietic diseases
Hematology
Hemoglobin
Humans
Identification and classification
Karyotypes
Karyotyping
Letters to the editor
Leukemia
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - genetics
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical prognosis
Medical sciences
Middle Aged
Myelodysplastic syndrome
Myelodysplastic syndromes
Myelodysplastic Syndromes - drug therapy
Myelodysplastic Syndromes - genetics
Neutrophils
Patients
Risk
Sepsis
Thalidomide - administration & dosage
Thalidomide - analogs & derivatives
Toxicity
France
Antineoplastic agent
High risk
Acute myelogenous leukemia
Hematology
Lenalidomide
Malignant hemopathy
Myelodysplastic syndrome
Azanucleoside
Treatment
Antimetabolic
Azacitidine
Triazine derivatives
Cytogenetics
Karyotype
Cancer
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0887-6924
1476-5551
DOI:10.1038/leu.2011.284